WallStreetZenWallStreetZen

NASDAQ: TECH
Bio Techne Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TECH

Based on 8 analysts offering 12 month price targets for Bio Techne Corp

Min Forecast
$65.00+12.32%
Avg Forecast
$73.63+27.22%
Max Forecast
$80.00+38.24%

Should I buy or sell TECH stock?

Based on 8 analysts offering ratings for Bio Techne Corp.

Strong Buy
Strong Buy
5 analysts 62.5%
Buy
1 analysts 12.5%
Hold
2 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although TECH's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates TECH as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their TECH stock forecasts and price targets.

TECH stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-06
lockedlocked$00.00+00.00%2026-02-05Find Out Why
lockedlocked$00.00+00.00%2026-02-05
lockedlocked$00.00+00.00%2026-02-05
lockedlocked$00.00+00.00%2026-02-05
Evercore ISI Group
Top 36%
65
HoldMaintains$68.00+17.50%2026-02-05
Argus Research
Top 20%
81
Strong BuyMaintains$68.00+17.50%2025-11-20Find out why
RBC Capital
Bottom 3%
3
BuyUpgrades$73.00+26.14%2025-09-03

1 of 1

Forecast return on equity

Is TECH forecast to generate an efficient return?

Company
21.86%
Industry
230.44%
Market
239.21%
TECH's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TECH forecast to generate an efficient return on assets?

Company
17.43%
Industry
108.07%
TECH is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TECH earnings per share forecast

What is TECH's earnings per share in the next 3 years based on estimates from 19 analysts?

Avg 1 year Forecast
$2.02+288.44%
Avg 2 year Forecast
$2.25+331.87%
Avg 3 year Forecast
$2.61+402.31%
TECH's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

TECH revenue forecast

What is TECH's revenue in the next 3 years based on estimates from 19 analysts?

Avg 1 year Forecast
$1.3B+2.83%
Avg 2 year Forecast
$1.3B+9.41%
Avg 3 year Forecast
$1.5B+20.03%
TECH's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TECH earnings growth forecast

How is TECH forecast to perform vs Biotechnology companies and vs the US market?

Company
70.59%
Industry
59.54%
Market
38.53%
TECH's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
TECH's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
TECH's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

TECH revenue growth forecast

How is TECH forecast to perform vs Biotechnology companies and vs the US market?

Company
6.01%
Industry
111.12%
Market
23.76%
TECH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TECH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TECH vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TECH$57.87$73.63+27.22%Strong Buy
PCVX$63.04$87.25+38.40%Strong Buy
ABVX$123.33$139.78+13.34%Strong Buy
ARWR$61.62$89.75+45.66%Strong Buy
PRAX$347.55$572.13+64.62%Strong Buy
View Top Biotech Stocks

Bio Techne Stock Forecast FAQ

Is Bio Techne Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: TECH) stock is to Strong Buy TECH stock.

Out of 8 analysts, 5 (62.5%) are recommending TECH as a Strong Buy, 1 (12.5%) are recommending TECH as a Buy, 2 (25%) are recommending TECH as a Hold, 0 (0%) are recommending TECH as a Sell, and 0 (0%) are recommending TECH as a Strong Sell.

If you're new to stock investing, here's how to buy Bio Techne stock.

What is TECH's earnings growth forecast for 2026-2028?

(NASDAQ: TECH) Bio Techne's forecast annual earnings growth rate of 70.59% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 59.54%, and it is also forecast to beat the US market's average forecast earnings growth rate of 38.53%.

Bio Techne's earnings in 2026 is $81,104,000.On average, 19 Wall Street analysts forecast TECH's earnings for 2026 to be $316,020,005, with the lowest TECH earnings forecast at $291,316,030, and the highest TECH earnings forecast at $335,122,951. On average, 18 Wall Street analysts forecast TECH's earnings for 2027 to be $351,347,158, with the lowest TECH earnings forecast at $321,980,875, and the highest TECH earnings forecast at $381,120,219.

In 2028, TECH is forecast to generate $408,655,999 in earnings, with the lowest earnings forecast at $358,778,689 and the highest earnings forecast at $478,043,034.

What is TECH's revenue growth forecast for 2026-2028?

(NASDAQ: TECH) Bio Techne's forecast annual revenue growth rate of 6.01% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 111.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.76%.

Bio Techne's revenue in 2026 is $1,215,577,000.On average, 19 Wall Street analysts forecast TECH's revenue for 2026 to be $195,566,615,000, with the lowest TECH revenue forecast at $186,961,683,940, and the highest TECH revenue forecast at $204,015,092,768. On average, 18 Wall Street analysts forecast TECH's revenue for 2027 to be $208,082,878,360, with the lowest TECH revenue forecast at $196,505,334,752, and the highest TECH revenue forecast at $217,782,982,464.

In 2028, TECH is forecast to generate $228,265,353,028 in revenue, with the lowest revenue forecast at $211,368,397,492 and the highest revenue forecast at $254,705,959,376.

What is TECH's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: TECH) forecast ROA is 17.43%, which is lower than the forecast US Biotechnology industry average of 108.07%.

What is TECH's Price Target?

According to 8 Wall Street analysts that have issued a 1 year TECH price target, the average TECH price target is $73.63, with the highest TECH stock price forecast at $80.00 and the lowest TECH stock price forecast at $65.00.

On average, Wall Street analysts predict that Bio Techne's share price could reach $73.63 by Feb 6, 2027. The average Bio Techne stock price prediction forecasts a potential upside of 27.22% from the current TECH share price of $57.87.

What is TECH's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: TECH) Bio Techne's current Earnings Per Share (EPS) is $0.52. On average, analysts forecast that TECH's EPS will be $2.02 for 2026, with the lowest EPS forecast at $1.86, and the highest EPS forecast at $2.14. On average, analysts forecast that TECH's EPS will be $2.25 for 2027, with the lowest EPS forecast at $2.06, and the highest EPS forecast at $2.44. In 2028, TECH's EPS is forecast to hit $2.61 (min: $2.29, max: $3.06).

What is TECH's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: TECH) forecast ROE is 21.86%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.